Control of cellular events in urothelial tumours

**Location:** Room Stockholm (Hall B2, level 0)

**Chairs:** E. Compérat, Paris (FR)
K. Junker, Homburg (DE)
N. Malats, Madrid (ES)

**Aims and objectives of this presentation**
In this session, miRNA and long coding RNA in urothelial cancer will be highlighted. Their involvement in oncogenic and tumour suppressive regulation of carcinogenesis will be presented. The session will also focus on innovative therapy applications in this malignancy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

*283*

**Intravesical instillation of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft**


**Institutes:** Osaka Medical College, Dept. of Urology, Osaka, Japan, 2Gifu University, United Graduate School of Drug Discovery and Medical Information Sciences, Gifu, Japan

*284*

**Intravesical delivery of hydrophobic drug using mucoadhesive cationic serum albumin nanoparticle as a carrier for bladder cancer therapy**

By: Chiong E., Lu S., Tan C., Rahmat J., Kang E.T., Mahendran R., Neoh K.G.

**Institutes:** National University Health System, Dept. of Urology, Singapore, Singapore, 2National University of Singapore, Dept. of Engineering, Singapore, Singapore, 3National University of Singapore, Dept. of Surgery, Singapore, Singapore

*285*

**mRNA expression levels and prognostic value of PD1/PDL1 and CTLA4 pathways genes in a large series of 155 bladder tumors**

By: Le Goux C., Bieche I., Barry De Longchamps N., Vacher S., Sibony M., Zerbib M., Damotte D., Pignot G.

**Institutes:** Institut Curie, Dept. of Pharmacogenomique, Paris, France, 2Hopital Cochin, Dept. of Urology, Paris, France, 3Hopital Cochin, Dept. of Anatomopathology, Paris, France, 4Institut Paoli-Calmettes, Dept. of Urology, Marseille, France

*286*

**Long noncoding RNAs in bladder cancer. Expression and quantification of MALAT1 in low and high risk tumors**


**Institutes:** Salamanca University Hospital, Dept. of Urology IBSAL-GITUR, Salamanca, Spain, 2Cancer Investigation Center of University of Salamanca, IBMCC, Salamanca, Spain, 3Research Unit of The University Hospital of Salamanca, Salamanca, Spain, 4Cancer Research (CIC-IBMCC;CSIC/USAL; IBSAL), Salamanca, Spain, 5Universitary and Hospitalary Salamanca´s Complex, Dept. of Oncology, Salamanca, Spain

*287*

**Targeting protein kinase CK2 suppresses bladder cancer cell survival via glycolysis pathway**

By: Tao T., Zhang X., Yang C., Cheng Y., Li P., Yang X., Deng X., Lu Q.
**Is two protein immunohistochemistry assay able to identify the basal subtype of bladder cancer?**

By: Masson-Lecomte A.¹, Sirab N.², De Reyniés A.³, Maille P.², Soyeux-Porte P.², Vordos D.¹¹, Lebret T.⁴, Benhamou S.⁵, Carrato A.⁶, Malats N.⁷, Real F.⁷, De La Taille A.¹¹, Radvanyi F.⁹, Allory Y.¹⁰

**Institutes:** Hôpitaux Universitaires Henri Mondor, Dept. of Urology, Créteil, France, ¹IMRB, Translational Research In Genito-Urinary Cancers, Créteil, France, ²Ligue Nationale Contre Le Cancer, Carte D’identité des Tumeurs Program, Paris, France, ³Foch Hospital, Dept. of Urology, Suresnes, France, ⁴INSERM, INSERM U946, Paris, France, ⁵Ramon Y Cajal Hospital, Dept. of Oncology, Madrid, Spain, ⁶CNIO, Genetic and Molecular Epidemiology Group, Madrid, Spain, ⁷CNIO, Epithelial Carcinogenesis Group, Madrid, Spain, ⁸CNRIS, Instituts Curie, UMR 144, Paris, France, ⁹Henri Mondor Hospital, Dept. of Pathology, Créteil, France, ¹⁰Henri Mondor Hospital, Dept. of Urology, Créteil, France

**Sulfated hyaluronic acid: A novel antitumor agent for bladder cancer**

By: Hennig M.¹, Jordan A.², Chipollini J.³, Hupe M.¹, Kramer M.¹, Lopez L.⁴, Merseburger A.¹, Lokeshwar V.⁶

**Institutes:** University of Lübeck, Dept. of Urology, Lübeck, Germany, ²Sylvester Comprehensive Cancer Center, University of Miami - Miller School of Medicine, Dept. of Urology, Miami, United States of America, ³University of Miami - Miller School of Medicine, Dept. of Urology, Miami, United States of America, ⁴Medical College of Georgia, Augusta University, Dept. of Biochemistry & Molecular Biology, Augusta, United States of America

**Topical and systemic immunoreaction induced by intravesical instillation of chemotherapeutic agents in a BBN-induced bladder cancer mouse model**


**Institutes:** Nara Medical University, Dept. of Urology, Nara, Japan

**Efficacy of recombinant bacille Calmette-Guérin secreting interleukin-15 against bladder cancer**

By: Takeuchi A., Tatsugami K., Shiota M., Yokomizo A., Inokuchi J., Kashiwagi E., Takashi D., Eto M.

**Institutes:** Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan

**Circulating tumour cells in patients with advanced urothelial carcinoma of the bladder and correlation with tumour stage, lymph node metastases and FDG-PET-findings**

By: Abrahamsson J.¹, Aaltonen K.², Engilbertsson H.¹, Lieberg F.¹, Patschan O.¹, Rydén L.², Sjödahl G.¹, Gudjonsson S.¹

**Institutes:** Lund University, Dept. of Translational Medicine, Dept. of Urology, Skåne University Hospital, Malmö, Sweden, ²Lund University, Dept. of Clinical Sciences, Dept. of Oncology, Lund, Sweden

**UroMark - a highly multiplex biomarker for the detection of bladder cancer**

By: Feber A.¹, De Winter P.², Dhami P.³, Martinez-Fernande M.⁴, Paul D.⁵, Hynes-Allen A.², Tan W.², Gurung P.², Rodney S.², Mehmood A.², Jameson C.⁶, Paramio J.⁴, Bryan R.¹, James N.⁷, Freeman A.⁶, Beck S.³, Kelly J.²

**Institutes:** UCL Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, ²UCL Medical School, Dept. of Surgery & Interventional Science, London, United Kingdom, ³UCL Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, ⁴CIEMAT, Molecular Oncology Unit, Madrid, Spain, ⁵UCL Cancer Insitute, Dept. of Cancer Biology, London, United Kingdom, ⁶University College London Hospital, Dept. of Histopathology, London, United Kingdom, ⁷University of Birmingham, School of Cancer Sciences, London, United Kingdom

**Hormonal receptor and Her2 status correlates independently of gender with staging and grading in non muscle-invasive urothelial bladder carcinoma**

By: Breyer J.¹, Wirtz R.², Denzinger S.¹, Erben P.³, Burger M.¹, Hartmann A.⁴, Otto W.¹
Institutes: 1University of Regensburg, Dept. of Urology, Regensburg, Germany, 2Stratifyer Molecular Pathology, Dept. of Pathology, Cologne, Germany, 3University of Mannheim, Dept. of Urology, Mannheim, Germany, 4University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany